

# Sammy Saab

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8782833/publications.pdf>

Version: 2024-02-01

244  
papers

9,055  
citations

28242

55  
h-index

53190

85  
g-index

246  
all docs

246  
docs citations

246  
times ranked

8795  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Long-term Outcomes of 3200 Liver Transplantations Over Two Decades. <i>Annals of Surgery</i> , 2005, 241, 905-918.	2.1	362
2	Hepatitis C virus infection in USA: an estimate of true prevalence. <i>Liver International</i> , 2011, 31, 1090-1101.	1.9	355
3	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. <i>Gastroenterology</i> , 2015, 148, 100-107.e1.	0.6	307
4	Long-Term Patient Outcome and Quality of Life After Liver Transplantation. <i>Annals of Surgery</i> , 2010, 252, 652-661.	2.1	242
5	A 10-Year Experience of Liver Transplantation for Hepatitis C: Analysis of Factors Determining Outcome in Over 500 Patients. <i>Annals of Surgery</i> , 2001, 234, 384-394.	2.1	234
6	MELD score predicts 1-year patient survival post-orthotopic liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 473-476.	1.3	177
7	The Evolution of Liver Transplantation During 3 Decades. <i>Annals of Surgery</i> , 2013, 258, 409-421.	2.1	177
8	Pregnancy and cirrhosis. <i>Liver Transplantation</i> , 2008, 14, 1081-1091.	1.3	173
9	Impact of coffee on liver diseases: a systematic review. <i>Liver International</i> , 2014, 34, 495-504.	1.9	161
10	Liver Transplantation for Fulminant Hepatic Failure. <i>Annals of Surgery</i> , 2003, 237, 666-676.	2.1	157
11	Major Challenges Limiting Liver Transplantation in the United States. <i>American Journal of Transplantation</i> , 2011, 11, 1773-1784.	2.6	149
12	Pretransplant Model to Predict Posttransplant Survival in Liver Transplant Patients. <i>Annals of Surgery</i> , 2002, 236, 315-323.	2.1	144
13	Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. <i>JAMA Network Open</i> , 2020, 3, e201997.	2.8	141
14	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. <i>Nature Communications</i> , 2020, 11, 4489.	5.8	134
15	Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: A systematic review. <i>Liver Transplantation</i> , 2010, 16, 300-307.	1.3	120
16	MELD fails to measure quality of life in liver transplant candidates. <i>Liver Transplantation</i> , 2005, 11, 218-223.	1.3	113
17	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013, 57, 1752-1762.	3.6	113
18	The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. <i>JAMA Internal Medicine</i> , 2014, 174, 204.	2.6	113

#	ARTICLE	IF	CITATIONS
19	Health-Related Quality of Life Predicts Mortality in Patients With Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 793-799.	2.4	110
20	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 544-563.	1.9	108
21	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 518-531.	1.9	107
22	Outcomes of acute rejection after interferon therapy in liver transplant recipients. <i>Liver Transplantation</i> , 2004, 10, 859-867.	1.3	106
23	TIPS versus paracentesis for cirrhotic patients with refractory ascites. <i>The Cochrane Library</i> , 2006, , CD004889.	1.5	99
24	New Era of Liver Transplantation for Hepatitis B. <i>Annals of Surgery</i> , 2002, 235, 611-620.	2.1	97
25	Oral Antibiotic Prophylaxis Reduces Spontaneous Bacterial Peritonitis Occurrence and Improves Short-Term Survival in Cirrhosis: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 993-1001.	0.2	91
26	Management of hepatocellular carcinoma with portal vein thrombosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 3462.	1.4	90
27	Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e61.	1.3	87
28	Nonalcoholic Fatty Liver Disease in Latinos. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 5-12.	2.4	87
29	Liver and Intestine Transplantation in the United States, 1995-2004. <i>American Journal of Transplantation</i> , 2006, 6, 1170-1187.	2.6	85
30	Treatment of hepatitis C. <i>American Journal of Medicine</i> , 2005, 118, 808-815.	0.6	78
31	Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1525-1534.	1.3	77
32	Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 182-187.	1.3	76
33	Hepatitis C Positive Grafts may be used in Orthotopic Liver Transplantation: A Matched Analysis. <i>American Journal of Transplantation</i> , 2003, 3, 1167-1172.	2.6	73
34	Employment and quality of life in liver transplant recipients. <i>Liver Transplantation</i> , 2007, 13, 1330-1338.	1.3	73
35	Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. <i>Liver International</i> , 2015, 35, 30-36.	1.9	73
36	Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. <i>Liver International</i> , 2010, 30, 948-957.	1.9	72

#	ARTICLE	IF	CITATIONS
37	The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85,000 liver transplant recipients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 686-694.	1.9	72
38	The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. <i>Liver International</i> , 2015, 35, 164-170.	1.9	71
39	Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy. <i>American Journal of Transplantation</i> , 2011, 11, 511-517.	2.6	70
40	Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. <i>American Journal of Gastroenterology</i> , 2003, 98, 763-770.	0.2	69
41	Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 923-930.	2.4	69
42	Serum Alanine Aminotransferase in Hepatitis C Screening of Patients on Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2001, 37, 308-315.	2.1	67
43	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016, 63, 1112-1119.	3.6	67
44	Hepatocellular carcinoma screening in patients waiting for liver transplantation: A decision analytic model. <i>Liver Transplantation</i> , 2003, 9, 672-681.	1.3	66
45	EUS-guided fine-needle core liver biopsy sampling using a novel 19-gauge needle with modified 1-pass, 1 actuation wet suction technique. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 469-475.	0.5	66
46	Health-related quality of life after liver transplantation for adult recipients. <i>Liver Transplantation</i> , 2009, 15, S42-S49.	1.3	63
47	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.	1.9	62
48	Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. <i>Liver International</i> , 2016, 36, 986-993.	1.9	62
49	Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. <i>Gastroenterology</i> , 2000, 119, 1382-1384.	0.6	61
50	Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. <i>Liver International</i> , 2008, 28, 28-38.	1.9	61
51	Extrahepatic Manifestations of Primary Biliary Cholangitis. <i>Gut and Liver</i> , 2017, 11, 771-780.	1.4	61
52	Prevalence and Risk Factors for Diabetes Mellitus in Moderate Term Survivors of Liver Transplantation. <i>American Journal of Transplantation</i> , 2006, 6, 1890-1895.	2.6	60
53	Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 1053-1061.	1.3	59
54	Treating hepatitis C in the prison population is cost-saving. <i>Hepatology</i> , 2008, 48, 1387-1395.	3.6	58

#	ARTICLE	IF	CITATIONS
55	Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model. <i>Liver Transplantation</i> , 2010, 16, NA-NA.	1.3	58
56	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2019, 3, 302-310.	1.2	58
57	Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. <i>Journal of Rheumatology</i> , 1998, 25, 801-6.	1.0	56
58	Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. <i>Hepatology</i> , 2018, 67, 847-857.	3.6	55
59	Apparent Remission of a Solitary Metastatic Pulmonary Lesion in a Liver Transplant Recipient Treated with Sorafenib. <i>American Journal of Transplantation</i> , 2009, 9, 2851-2854.	2.6	53
60	Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. <i>Hepatology</i> , 2007, 46, 1049-1056.	3.6	52
61	Patient Satisfaction and Healthcare Utilization Using Telemedicine in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1150-1157.	1.1	51
62	Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. <i>Gut and Liver</i> , 2016, 10, 509-519.	1.4	50
63	Prospective validation of the short form liver disease quality of life instrument. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1088-1101.	1.9	46
64	Viral Hepatitis in Incarcerated Adults: A Medical and Public Health Concern. <i>American Journal of Gastroenterology</i> , 2009, 104, 1024-1031.	0.2	45
65	Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. <i>Liver International</i> , 2015, 35, 2442-2447.	1.9	44
66	Economic Burden Associated With Patients Diagnosed With Hepatitis C. <i>Clinical Therapeutics</i> , 2011, 33, 1268-1280.	1.1	43
67	Fibrolamellar hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1981-1985.	1.1	38
68	Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors. <i>Liver Transplantation</i> , 2011, 17, 580-590.	1.3	38
69	The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013. <i>JAMA Internal Medicine</i> , 2014, 174, 1407.	2.6	38
70	Management of Thrombocytopenia in Patients with Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2757-2768.	1.1	38
71	Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx109.	0.4	37
72	Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. <i>Liver Transplantation</i> , 2007, 13, 1032-1038.	1.3	36

#	ARTICLE	IF	CITATIONS
73	Toward the elimination of hepatitis C in the United States. <i>Hepatology</i> , 2018, 67, 2449-2459.	3.6	36
74	Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. <i>World Journal of Gastroenterology</i> , 2015, 21, 8271.	1.4	36
75	Liver transplantation in the era of model for end-stage liver disease. <i>Liver International</i> , 2004, 24, 1-8.	1.9	34
76	Incidence of abnormal liver biochemical tests in hyperthyroidism. <i>Clinical Endocrinology</i> , 2017, 86, 755-759.	1.2	34
77	Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584.	0.2	33
78	Hepatitis C Infection in the Elderly. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3170-3180.	1.1	33
79	Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4574-4580.	1.1	33
80	Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. <i>Korean Journal of Radiology</i> , 2016, 17, 472.	1.5	32
81	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. <i>Medicine (United States)</i> , 2016, 95, e5048.	0.4	32
82	Management of Hepatitis C Antiviral Therapy Adverse Effects. <i>Current Hepatitis Reports</i> , 2011, 10, 33-40.	0.3	31
83	Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?. <i>Liver Transplantation</i> , 2002, 8, 449-457.	1.3	30
84	Recurrence of non-viral liver disease after orthotopic liver transplantation. <i>Liver International</i> , 2011, 31, 291-302.	1.9	30
85	TIPS versus paracentesis for cirrhotic patients with refractory ascites. , 2004, , CD004889.		29
86	Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 413-420.	1.3	29
87	Cirrhosis Regression in Patients With Viral Hepatitis B and C. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, e76-e84.	1.1	29
88	A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination. <i>American Journal of Medicine</i> , 2000, 109, 241-244.	0.6	28
89	Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. <i>Liver Transplantation</i> , 2013, 19, 1020-1029.	1.3	28
90	The outcomes of adult liver transplants in the United States from 1987 to 2013. <i>Liver International</i> , 2015, 35, 2036-2041.	1.9	28

#	ARTICLE	IF	CITATIONS
91	Presumed Consent: A Potential Tool for Countries Experiencing an Organ Donation Crisis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1346-1355.	1.1	28
92	Complications of Cirrhosis. <i>Disease-a-Month</i> , 2008, 54, 445-456.	0.4	27
93	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015, 15, 175.	0.8	27
94	Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. <i>Liver International</i> , 2017, 37, 1877-1886.	1.9	27
95	Management of Patients With Cirrhosis in Southern California. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 156-161.	1.1	26
96	Management of Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients: A Systematic Review. <i>Experimental and Clinical Transplantation</i> , 2012, 10, 531-543.	0.2	25
97	The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. <i>Liver International</i> , 2010, 30, 19-30.	1.9	24
98	Development of a disease-specific questionnaire to measure health-related quality of life in liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 567-579.	1.3	24
99	Effects of Clostridium difficile Infection in Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1745-1752.e2.	2.4	24
100	Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017, 66, 46-56.	3.6	24
101	Transjugular Liver Biopsy: Safe Even in Patients With Severe Coagulopathies and Multiple Biopsies. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00063.	1.3	24
102	Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. <i>Experimental and Clinical Transplantation</i> , 2010, 8, 307-13.	0.2	24
103	Seroepidemiology of hepatitis A in patients with chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2005, 12, 101-105.	1.0	23
104	Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. <i>International Journal of General Medicine</i> , 2015, 8, 165.	0.8	23
105	Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2018, 113, 1187-1196.	0.2	23
106	Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. <i>World Journal of Gastroenterology</i> , 2016, 22, 5780.	1.4	23
107	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	1.3	22
108	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.	1.1	22

#	ARTICLE	IF	CITATIONS
109	Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. <i>Advances in Therapy</i> , 2018, 35, 1087-1102.	1.3	22
110	Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin-1. <i>Journal of Biomedical Science</i> , 2002, 9, 607-612.	2.6	21
111	Liver Transplantation and Bariatric Surgery. <i>Clinics in Liver Disease</i> , 2017, 21, 215-230.	1.0	21
112	EUS-guided fine-needle core liver biopsy with a modified one-pass, one-actuation wet suction technique comparing two types of EUS core needles. <i>Endoscopy International Open</i> , 2020, 08, E938-E943.	0.9	21
113	Treating Medicaid patients with hepatitis C: clinical and economic impact. <i>American Journal of Managed Care</i> , 2017, 23, 107-112.	0.8	21
114	Same day outpatient transjugular liver biopsies in haemophilia. <i>Haemophilia</i> , 2004, 10, 727-731.	1.0	20
115	Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. <i>Liver International</i> , 2005, 25, 940-945.	1.9	20
116	Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. <i>Clinics in Liver Disease</i> , 2019, 23, 607-623.	1.0	20
117	Hepatitis C and Work Impairment. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 595-599.	1.1	19
118	Treating fibrosing cholestatic hepatitis <scp>C</scp> with sofosbuvir and ribavirin: a matched analysis. <i>Clinical Transplantation</i> , 2015, 29, 813-819.	0.8	19
119	New Face of Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1782-1788.	1.1	19
120	Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 76-82.	0.7	19
121	Relationship between Telomere Maintenance and Liver Disease. <i>Gut and Liver</i> , 2019, 13, 11-15.	1.4	19
122	Recurrent Hepatitis C Following Liver Transplant. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 155-163.	1.1	18
123	Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. <i>Clinics in Liver Disease</i> , 2019, 23, 589-605.	1.0	18
124	Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 309-313.	1.1	18
125	Discordance Between ALT Values and Fibrosis in Liver Transplant Recipients Treated with Ribavirin for Recurrent Hepatitis C. <i>American Journal of Transplantation</i> , 2003, 3, 328-333.	2.6	17
126	Title is missing!. <i>Annals of Surgery</i> , 2003, 237, 666-676.	2.1	17



#	ARTICLE	IF	CITATIONS
127	Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. <i>Journal of Medical Economics</i> , 2016, 19, 795-805.	1.0	17
128	Endoscopic Ultrasound Liver Biopsies Accurately Predict the Presence of Fibrosis in Patients With Fatty liver. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1477-1478.	2.4	17
129	Primary prevention of cirrhosis. <i>Postgraduate Medicine</i> , 2004, 115, 25-30.	0.9	16
130	Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3124-3129.	1.1	16
131	The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. <i>BMC Gastroenterology</i> , 2016, 16, 129.	0.8	16
132	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017, 37, 662-668.	1.9	16
133	Tyrosine phosphorylation of p125fak, p130cas, and paxillin does not require extracellular signal-regulated kinase activation in swiss 3T3 cells stimulated by bombesin or platelet-derived growth factor. <i>Journal of Cellular Physiology</i> , 2000, 183, 208-220.	2.0	15
134	Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. <i>World Journal of Gastroenterology</i> , 2015, 21, 8140.	1.4	15
135	Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 789-796.	1.0	15
136	De novo Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 284-287.	0.7	15
137	Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 32-38.	0.7	15
138	Tests for acute and chronic viral hepatitis. <i>Postgraduate Medicine</i> , 2000, 107, 123-130.	0.9	14
139	Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. <i>Clinical Diabetes</i> , 2017, 35, 79-83.	1.2	14
140	Impact of Nutrition and Obesity on Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 205-218.	1.0	13
141	Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2829-2839.	1.1	13
142	Rural-Urban Geographical Disparities in Hepatocellular Carcinoma Incidence Among US Adults, 2004-2017. <i>American Journal of Gastroenterology</i> , 2021, 116, 401-406.	0.2	13
143	Myosin Mediates Contractile Force Generation by Hepatic Stellate Cells in Response to Endothelin-1. <i>Journal of Biomedical Science</i> , 2002, 9, 607-612.	2.6	13
144	LIVER TRANSPLANTATION. <i>Clinics in Liver Disease</i> , 2000, 4, 513-532.	1.0	12

#	ARTICLE	IF	CITATIONS
145	Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients. <i>Vaccine</i> , 2002, 20, 3230-3235.	1.7	12
146	Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles's Skid Row. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3023-3031.	1.1	12
147	The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 45-81.	0.4	12
148	Patients with nodular regenerative hyperplasia should be considered for hepatocellular carcinoma screening. <i>Hepatology Research</i> , 2014, 44, 689-693.	1.8	11
149	Boceprevir in liver transplant recipients. <i>Liver International</i> , 2015, 35, 192-197.	1.9	11
150	Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. <i>Advances in Therapy</i> , 2016, 33, 1316-1330.	1.3	11
151	Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 360-363.	1.1	11
152	Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 167-173.	1.1	11
153	Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B. <i>Clinical Transplantation</i> , 2019, 33, e13740.	0.8	11
154	Clinical evaluation of a hepatitis C antibody rapid immunoassay on self-collected oral fluid specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 149-151.	0.8	11
155	Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient. <i>Journal of Hepatology</i> , 2005, 42, 148-149.	1.8	10
156	The Management of Hepatitis B in Liver Transplant Recipients. <i>Clinics in Liver Disease</i> , 2016, 20, 721-736.	1.0	10
157	Cardiovascular and metabolic disease in the liver transplant recipient. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101683.	1.0	10
158	Practical Tips on TIPS: When and When Not to Request It. <i>American Journal of Gastroenterology</i> , 2020, 115, 797-800.	0.2	10
159	Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 503-511.	1.1	10
160	Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1994-2004.	1.1	10
161	Hepatitis C Screening: Barriers to Linkage to Care. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-6.	0.7	10
162	Impact of solid organ transplant status on outcomes of hospitalized patients with COVID-19 infection. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	10

#	ARTICLE	IF	CITATIONS
163	Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. <i>Clinical Transplantation</i> , 2013, 27, 829-837.	0.8	9
164	Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2835-2848.	0.9	9
165	Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for <sc>US</sc> Post-liver Transplant Recurrent Genotype 1 <sc>HCV</sc>. <i>Liver International</i> , 2016, 36, 515-521.	1.9	9
166	Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1110-1118.	1.1	9
167	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 755-769.	1.0	9
168	Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics. <i>Journal of Viral Hepatitis</i> , 2020, 27, 762-769.	1.0	9
169	Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavirin in Liver Transplant Recipients with Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-8.	0.7	9
170	Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. <i>Advances in Therapy</i> , 2021, 38, 5777-5790.	1.3	9
171	Evolving Misidentification Syndromes and Facial Recognition Deficits<sup>*</sup>. <i>Canadian Journal of Psychiatry</i> , 1992, 37, 574-576.	0.9	8
172	Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective. <i>Clinical Transplantation</i> , 2018, 32, e13383.	0.8	8
173	Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2483-2491.	1.1	8
174	History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00378.	1.3	8
175	Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive Setting. <i>Liver Transplantation</i> , 2022, 28, 200-214.	1.3	8
176	Medical Management of Metabolic Complications of Liver Transplant Recipients. <i>Gastroenterology and Hepatology</i> , 2016, 12, 601-608.	0.2	8
177	Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. <i>Current Hepatitis Reports</i> , 2010, 9, 147-154.	0.3	7
178	<sc>HCV</sc> infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015, 29, 920-926.	0.8	7
179	Disparities in Mortality and Health Care Utilization for 460,851 Hospitalized Patients with Cirrhosis and Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2595-2602.	1.1	7
180	The Urgent Need for Hepatitis C Screening in Pregnant Women. <i>Obstetrics and Gynecology</i> , 2020, 135, 773-777.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. <i>Gastroenterology and Hepatology</i> , 2014, 10, 175-9.	0.2	7
182	Pretransplant variables associated with quality of life in liver transplant recipients. <i>Liver International</i> , 2008, 28, 1087-1094.	1.9	6
183	Spotlight on grazoprevir&mdash;elbasvir once-daily combination and its potential in the treatment of hepatitis C. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2119-2127.	2.0	6
184	Inpatient Cost Assessment of Transjugular Intrahepatic Portosystemic Shunt in the USA from 2001 to 2012. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2838-2846.	1.1	6
185	Nonobese nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2017, 10, 130-133.	1.0	6
186	Barriers for Liver Transplant in Patients with Alcohol-Related Hepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 13-19.	0.4	6
187	Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. <i>Lipids in Health and Disease</i> , 2021, 20, 136.	1.2	6
188	Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 595-606.	1.0	5
189	Effect of ombitasvir/paritaprevir/ritonavir&Aacute;dasabuvir regimen on health&Aacute;related quality of life for patients with hepatitis C. <i>Liver International</i> , 2018, 38, 1377-1394.	1.9	5
190	Elimination of Hepatitis C in Liver Transplant Recipients. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-4.	0.7	5
191	Approaches to Assessing Burden in Caregivers of Patients with Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 127-134.	0.7	5
192	Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. <i>Gastroenterology and Hepatology</i> , 2016, 12, 23-30.	0.2	5
193	Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2015, 11, 294-346.	0.2	5
194	Coffee as modulator of liver injury: Fact and fiction. <i>Clinical Liver Disease</i> , 2015, 6, 139-141.	1.0	4
195	Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Na&Aacute;ve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA&Aacute;6 Million IU/mL. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3480-3486.	1.1	4
196	Covalent Chemistry&Aacute;Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. <i>Advanced Materials Technologies</i> , 2021, 6, 2001056.	3.0	4
197	The MELD score in advanced liver disease: association with clinical portal hypertension and mortality. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 395-9.	0.2	4
198	Hepatitis C treatment threshold in patients with decompensated liver disease. <i>Hepatology</i> , 2017, 65, 1789-1791.	3.6	3

#	ARTICLE	IF	CITATIONS
199	Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance. <i>BMC Infectious Diseases</i> , 2019, 19, 626.	1.3	3
200	Abstract 24: Multi-feature ensemble learning on cell-free dna for accurately detecting and locating cancer. <i>Cancer Research</i> , 2021, 81, 24-24.	0.4	3
201	Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 20-25.	0.7	3
202	Case Series Review of the Safety and Efficacy of Endoscopic Ultrasound-Guided Splenic Mass Core Biopsy. <i>Clinical Endoscopy</i> , 2018, 51, 600-601.	0.6	3
203	The Current Status of Hepatitis C. <i>International Journal of Artificial Organs</i> , 2001, 24, 838-842.	0.7	2
204	Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations. <i>Current Hepatitis Reports</i> , 2009, 8, 43-51.	0.3	2
205	Case Report: Patient with Hepatitis C, p-ANCA, and Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA Glomerulonephritis. <i>Case Reports in Nephrology and Dialysis</i> , 2018, 8, 161-170.	0.3	2
206	Estimating paediatric hepatitis C prevalence in the United States. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1455-1461.	1.0	2
207	Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma. <i>Experimental and Clinical Transplantation</i> , 2016, 14, 66-71.	0.2	2
208	Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 250-257.	1.1	2
209	Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 419-424.	0.2	2
210	Fulminant hepatic failure. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 473-479.	0.3	1
211	Outcomes of liver transplantation using Hepatitis B core-positive liver grafts: Implications for prophylaxis. <i>Current Hepatitis Reports</i> , 2006, 5, 33-39.	0.3	1
212	Response to Krag et al.. <i>American Journal of Gastroenterology</i> , 2010, 105, 1444-1445.	0.2	1
213	Can Daily Coffee Consumption Reduce Liver Disease-Related Mortality?. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1422-1423.	2.4	1
214	Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals. <i>Journal of Infectious Diseases</i> , 2015, 212, 343-344.	1.9	1
215	Innovative Linkage to Care for Patients With Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
216	Cultural validation of the post-Liver transplant quality of life (pLTQ) questionnaire for the Brazilian population. <i>Annals of Hepatology</i> , 2016, 15, 377-385.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Hepatitis C Virus Prevalence in Egyptian Americans in Southern California. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 55-59.	1.1	1
218	Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3719-3725.	1.1	1
219	Accuracy and Safety of 1,055 Transjugular Liver Biopsies in Postliver Transplant Patients. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00355.	1.3	1
220	Hematopoietic Abnormalities and Hemostasis. , 2012, , 405-413.		1
221	A Systematic Approach to Pregnancy-Specific Liver Disorders. <i>Gastroenterology and Hepatology</i> , 2021, 17, 322-329.	0.2	1
222	Endoscopic Ultrasound-Guided Liver Biopsy: Where Do We Stand?. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, .	0.2	1
223	Practical management of liver transplant recipients for hepatitis C. <i>Minerva Chirurgica</i> , 2003, 58, 479-89.	0.8	1
224	Lymphedema tarda after liver transplantation: a case report and review of the literature. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 567-70.	0.2	1
225	Trends in viral hepatitis cost-effectiveness studies. <i>American Journal of Managed Care</i> , 2012, 18, 790-8.	0.8	1
226	Liver disease. <i>Postgraduate Medicine</i> , 2000, 107, 95-96.	0.9	0
227	Update on management of hepatitis B before and after liver transplantation. <i>Current Hepatitis Reports</i> , 2008, 7, 25-32.	0.3	0
228	Approach to the Patient with Chronic Viral Hepatitis B or C. , 0, , 516-525.		0
229	IUD in transplant recipients. <i>Liver International</i> , 2009, 29, 475-476.	1.9	0
230	Interferon for Hepatitis B: Which Populations Benefit the Most. <i>Current Hepatitis Reports</i> , 2011, 10, 285-291.	0.3	0
231	Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. <i>Current Hepatitis Reports</i> , 2013, 12, 13-19.	0.3	0
232	Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 984-985.	1.9	0
233	Portal Hypertension. <i>Clinics in Liver Disease</i> , 2019, 23, xiii-xiv.	1.0	0
234	Casting a Wider NET: An Unusual Cause of Acute Liver Failure in a Pregnant Patient. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3102-3105.	1.1	0

#	ARTICLE	IF	CITATIONS
235	Frailty Does Not Impact Caregiver Burden in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3343-3351.	1.1	0
236	Acute Liver Failure During Pregnancy: Happy to Recover from Hep E. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2515-2517.	1.1	0
237	Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 9-12.	0.7	0
238	Algorithm to Evaluate Abnormal Liver Function Tests in Liver Transplant Patientsâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1110.	3.8	0
239	AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia. <i>Digestive Diseases and Sciences</i> , 2021, 67, 67.	1.1	0
240	Treating HCV After Liver Transplantation. , 2012, , 313-323.		0
241	Disease Recurrence After Liver Transplantation: Quality of Life and Cost of Retransplantation. , 2016, , 245-258.		0
242	Surveillance for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2014, 10, 745-747.	0.2	0
243	Current Treatment of Thrombocytopenia in Chronic Liver Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 558-560.	0.2	0
244	Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	0